Skip to main content
. 2024 Mar 18;4(3):822–833. doi: 10.1158/2767-9764.CRC-23-0513

FIGURE 6.

FIGURE 6

IDO1/TDO2 inhibition combined with cisplatin attenuates cisplatin-induced PD-L1 and extends overall survival. A, COV504 treated for 48 hours with control, cisplatin (10 µmol/L), or cisplatin (10 µmol/L)/AT-0174 (5 µmol/L). PD-L1 expression was measured via flow cytometry. B, ID8 (Tp53−/−) syngeneic animal study with cisplatin (i.p., weekly, 0.5 mg/kg) and/or AT-0174 (oral gavage, daily, 120 mg/kg). n = 10 mice/group C). Kaplan–Meier curve of animal study described in B. Error bars, SEM. Statistical test, multicomparison ANOVA (A) and log-rank (C).